Synovis Life Technologies, Inc. (NASDAQ: SYNO), a diversified medical device manufacturer, will broadcast the use of Veritas® Collagen Matrix in a component separation procedure for complex abdominal wall reconstruction at 7 p.m. ET on Wednesday, April 30, on ORLive™ (www.or-live.com). Veritas Collagen Matrix is an innovative biological material which remodels into the tissue it is used to repair.
This procedure will be performed by Jerome D. Chao, MD, FACS, Assistant Professor of Surgery, Director, Plastic Surgery Trauma – Department of Surgery, Division of Plastic Surgery, Albany Medical College; and Dimitri J. Koumanis, MD, Assistant Professor of Surgery, Department of Surgery, Division of Plastic Surgery, Albany Medical College.
“Physicians are turning to Veritas as a solution for challenging surgical situations,” said Richard Kramp, Synovis Life Technologies president and chief executive officer. “In addition to complex abdominal wall repair, Veritas provides a strong and stable scaffold for tissue remodeling in procedures such as hiatal hernia repair, chest wall reconstruction and breast reconstruction. We would like to thank ORLive, and Drs. Chao and Koumanis for participating in this educational video on component separation with Veritas.”
Health care professionals and the general public can send questions to Drs. Chao and Koumanis during the broadcast and the following week. They will address questions during this period as time permits.
Veritas Collagen Matrix is an innovative, non-cross-linked, biologic material derived from bovine pericardium indicated for use as an implant for the surgical repair of soft tissue deficiencies, including abdominal and thoracic wall repair, muscle flap reinforcement and repair of hernias. Veritas is produced through a patented process that results in an extremely biocompatible and highly acellular remodelable material. Once implanted, Veritas provides a scaffold for connective tissue protein synthesis and host tissue in-growth. The result is the seamless integration of Veritas into the surrounding host tissue.
Veritas has been used successfully in contaminated wounds and in the presence of infection, as well as other challenging situations. The U.S. Food and Drug Administration granted Synovis the following additional indication: Veritas minimizes tissue attachment to the material when in direct contact with viscera. Veritas was the first biologic material to have received this important indication from the FDA.
About Synovis Life Technologies
Synovis Life Technologies, Inc. (NASDAQ: SYNO), based in St. Paul, Minn., is a diversified medical device company engaged in developing, manufacturing and bringing to market medical devices for the surgical treatment of disease. For additional information on Synovis Life Technologies, visit the company’s Web site at www.synovislife.com.
Contacts:
Nancy A. Johnson, 612-455-1745
or
Marian
Briggs, 612-455-1742
or
Synovis Life Technologies, Inc.
Richard
Kramp, President and CEO, 651-796-7300
or
Brett Reynolds, CFO,
651-796-7300
